A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

The next major AI breakthrough will come from applying generative models to complex systems beyond human language, such as biology. By treating biological processes as a unique "language," AI could discover novel therapeutics or research paths, leading to a "Move 37" moment in science.

AI models trained on descriptive data (e.g., RNA-seq) can classify cell states but fail to predict how to transition a diseased cell to a healthy one. True progress requires generating massive "causal" datasets that show the effects of specific genetic perturbations.

The primary obstacle to creating sophisticated AI models of cells isn't the AI itself, but the data. Existing datasets often perturb only one cellular variable at a time, failing to capture the complex interactions that arise from simultaneous changes. New platforms are needed to generate this multi-dimensional data.

The next frontier in preclinical research involves feeding multi-omics and spatial data from complex 3D cell models into AI algorithms. This synergy will enable a crucial shift from merely observing biological phenomena to accurately predicting therapeutic outcomes and patient responses.

Despite AI's rapid progress, David Sinclair states that fully simulating a single biological cell from the atomic level is beyond near-future computing. The quantum effects and sheer number of molecular interactions present a challenge that will likely require quantum computers.

The ultimate goal isn't just modeling specific systems (like protein folding), but automating the entire scientific method. This involves AI generating hypotheses, choosing experiments, analyzing results, and updating a 'world model' of a domain, creating a continuous loop of discovery.

Following the success of AlphaFold in predicting protein structures, Demis Hassabis says DeepMind's next grand challenge is creating a full AI simulation of a working cell. This 'virtual cell' would allow researchers to test hypotheses about drugs and diseases millions of times faster than in a physical lab.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.